id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-029882-kufs0fxe	Malviya, Amit	The continued dilemma about usage of Hydroxychloroquine: Respite is in randomized control trials	2020-07-29		.txt	text/plain	483	34	57	HCQ is touted for treatment of Covid 19 primarily based on its anti-viral properties, thus the timing of administration becomes very important for a meaning full assessment of study results. Recently it been shown that this score is not accurate for predicting severity of disease in Covid 19 patients . Covid 19 is a multisystem disease and the disease itself promotes proarrhythmic milieu with prolonged QT intervals at baseline .5,6 Risk assessment of HCQ therapy is not complete if such patients are excluded. Finally , mechanism of action of HCQ against is a part of its broad anti-viral and immunomodulatory properties and no specific pharmacologic actions are described for SARS-CoV-2 infection. 9,10 Weather HCQ as initial anti-viral agent prevents progression to severe disease is not known clearly . Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given Effects of chloroquine on viral infections: an old drug against today's diseases?	./cache/cord-029882-kufs0fxe.txt	./txt/cord-029882-kufs0fxe.txt